Reports Q3 revenue $9.83M, consensus $9.54M. "I am pleased with this quarter’s growth in Total Bylvay PFIC patients and Bylvay sales. With the new native liver survival evidence presented at scientific congresses, our value proposition has strengthened. On top of that, we believe the recently announced positive ASSERT Phase 3 results will give us access to Alagille patients which are an additional and larger patient community than PFIC," said Ron Cooper, president and CEO of Albireo. "We are expanding Bylvay’s reach even further as our Phase 3 BOLD study in biliary atresia is fully enrolled with topline results planned for 2024. Having completed a royalty monetization deal for Bylvay we strengthened our cash runway, providing enough resources to execute on our plans for Bylvay, A3907 and A2342."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ALBO:
- Albireo Reports Q3 2022 Financial Results and Business Update
- American Association for Study of Liver Diseases to hold a meeting
- Albireo Pharma presented data on Bylvay at the AASLD The Liver Meeting
- Bylvay® (odevixibat) Data Presented at AASLD The Liver Meeting® 2022, Demonstrating Native Liver Survival in Children Across PFIC Types
- Albireo Announces 2022 SPARK Grant Winners